Related by context. All words. (Click for frequent words.) 74 relapsed MM 72 treatment naive genotype 72 blinded randomized placebo controlled 72 refractory CLL 72 subcutaneous PRO 72 riociguat 71 oral rivaroxaban 71 mg/m2 cohort 71 recurrent glioblastoma multiforme 70 thorough QT 70 phase Ib 70 CHAMPION PCI 70 evaluable subjects 70 Phase IIIb clinical 69 APTIVUS r 69 Raptiva r 69 null responder HCV 69 antiretroviral naïve 69 alvespimycin 69 BRIM2 68 oral methylnaltrexone 68 heavily pretreated 68 dose titration 68 ascending dose 68 APEX AMI 68 relapsed refractory multiple myeloma 68 randomized multicenter trial 68 DEB# 68 Zemplar Capsules 68 phase IIb study 68 dosing cohort 68 randomized blinded 68 Traficet EN 68 CIMZIA TM certolizumab pegol 68 galiximab 68 RSD# oral 68 CIMZIA TM 68 azilsartan medoxomil 68 NATRECOR R 68 weekly subcutaneous injections 68 Phase Ib clinical 68 CIMZIA ™ 68 ZOLINZA 68 IMPACT DCM clinical 68 MAGE A3 ASCI 68 IEQ kg 67 APTIVUS 67 GSK# [001] 67 YONDELIS 67 opioid naive 67 randomized Phase IIb 67 Randomized controlled 67 bepotastine besilate nasal spray 67 antiretroviral naive 67 PRIMO CABG 67 dose cohort 67 ABSORB trial 67 dose escalation clinical 67 placebo controlled clinical 67 PegIFN RBV 67 MVax 67 rALLy trial 67 Phase Ib II 67 GAMMAGARD 67 dose dose escalation 67 via intradermal injections 67 CUSTOM III 67 Phase #b/#a 67 bortezomib refractory 67 Phase 1a clinical 67 eosinophilic asthma 67 recurrent glioma 67 ALN VSP Phase 67 Dacogen injection 67 STRIDE PD 67 BRIM3 67 Twinrix 67 placebo controlled dose escalation 67 Ceplene/IL-2 67 PROMACTA 67 double blinded placebo 67 phase IIb trial 67 GOUT 67 IMPACT DCM 66 randomized Phase 2b 66 phase IIa 66 treatment naïve genotype 66 Bezielle 66 de novo kidney transplant 66 MGd 66 dosing cohorts 66 certolizumab 66 budesonide foam 66 BENICAR HCT 66 urocortin 2 66 moderate renal impairment 66 R# #mg BID 66 GetGoal Phase III 66 Phase Ib study 66 Phase #/#a 66 elective PCI 66 rindopepimut 66 phase IIb clinical 66 weekly intravenous infusions 66 CAMMS# 66 #mg dosing group 66 CLARITY study 66 rALLy 66 active comparator 66 ABSORB clinical 66 mg/m2 dose 66 HCV RESPOND 2 66 Dose escalation 66 Primary endpoints 66 Bayer HealthCare Onyx Pharmaceuticals 66 achieved CCyR 66 CHOP chemotherapy 66 teriflunomide 66 forodesine 66 Phase IIB 66 refractory metastatic 66 PREZISTA r 66 pharmacodynamic effects 66 recombinant PSMA vaccine 66 ritonavir boosted 66 microgram kg 66 SIMPADICO 66 Forodesine HCl 66 LibiGel Phase III 66 Acute Decompensated Heart Failure 66 NSABP B 66 RRMS patients 66 double blinded randomized 66 nab paclitaxel 66 ENESTnd 66 desvenlafaxine succinate 66 crizotinib PF # 66 recurrent metastatic ovarian cancer 66 AIR CF1 66 PSMA ADC 66 Diamyd r 66 oral FTY# 65 refractory NSCLC 65 trastuzumab Herceptin ® 65 novel VDA molecule 65 HCV SPRINT 65 intermittent dosing 65 Secondary efficacy endpoints 65 EXJADE 65 NO# [002] 65 methotrexate monotherapy 65 rALLy clinical trial 65 EXPLORE Xa 65 placebo controlled Phase III 65 AVOREN 65 canakinumab 65 intravenous dosing 65 samalizumab 65 PROCHYMAL 65 Pemetrexed 65 randomized #:#:# 65 antiangiogenic therapy 65 MEND CABG II 65 REVIVE Diabetes 65 postoperative chemotherapy 65 refractory AML 65 REVIVE TA 65 HuMax EGFr 65 Urocortin 2 65 subcutaneous methylnaltrexone 65 ganetespib 65 NATRECOR ® 65 neratinib 65 OPT CHF 65 genotypic resistance 65 Phase IIb III 65 BEXXAR therapeutic regimen 65 maximally tolerated dose 65 biliary tract cancer 65 multicenter Phase II 65 Golimumab 65 ACTEMRA TM 65 somatostatin analog 65 visceral metastases 65 bevirimat Study 65 Randomized Phase II 65 Tumor Response 65 Plicera 65 LEAPS H#N# 65 placebo controlled clinical trials 65 develop HBV reactivation 65 pegylated interferon alpha 65 Aflibercept 65 #I TM# 65 ATACAND 65 Phase III Pivotal 65 NOX E# 65 tramiprosate Alzhemed TM 65 ENDEAVOR IV 65 tanespimycin 65 aplindore 65 bolus dose 65 #mg QD [002] 65 HF ACTION 65 pharmacokinetic PK study 65 XL# SAR# 65 serum phosphorous 65 midstage clinical 65 systemic ALCL 65 Phase III randomized controlled 65 paclitaxel Taxol R 64 Virulizin ® 64 acyclovir Lauriad R 64 Fibrillex TM 64 metastatic GIST 64 Pharmacokinetic parameters 64 recurrent malignant glioma 64 decompensated liver disease 64 phase IIa clinical 64 TMC# r 64 Androxal TM 64 CYT# QbG# 64 CANCIDAS 64 Proellex TM 64 EchoCRT 64 oral talactoferrin 64 mg kg dose 64 relapsing remitting MS RRMS 64 Pegasys plus Copegus 64 Phase #b/#a clinical 64 prospectively stratified 64 Allovectin 7 ® 64 SYMMETRY trial 64 lipid lowering therapy 64 viral kinetics 64 visilizumab 64 naïve HCV 64 landmark ATHENA 64 designated HVTN 64 placebo controlled Phase 64 Phase Ib IIa 64 ASSERT trial 64 CYT# potent vascular disrupting 64 Subgroup analysis 64 Arranon 64 refractory chronic lymphocytic 64 estramustine 64 ELACYT 64 dose cohorts 64 CTAP# Capsules 64 ribavirin RBV 64 Tarceva TM 64 pharmacokinetic PK 64 multicenter randomized controlled 64 intradermal injections 64 randomized crossover 64 8mg/kg 64 Phase 2a trial 64 blinded randomized 64 icatibant 64 APTIVUS ritonavir 64 COU AA 64 intravenous RSD# 64 evaluable 64 patients evaluable 64 CATIE AD 64 doxorubicin docetaxel 64 #mg ATC 64 TAXOTERE R 64 sargramostim 64 recurrent glioblastoma 64 multicenter randomized placebo controlled 64 FOLPI 64 Cloretazine 64 mcg BID 64 ara C 64 mitoxantrone plus 64 multicenter Phase 64 oral prednisone 64 EMPHASIS HF trial 64 AGILECT R 64 randomized controlled multicenter 64 cilengitide 64 nonmetastatic prostate cancer 64 unresectable malignant mesothelioma UMM 64 oral ridaforolimus 64 CHARM Added 64 ongoing Phase 1b 64 Randomized Phase 64 CALGB # [002] 64 decitabine 64 lomitapide 64 lenalidomide Revlimid R 64 venlafaxine ER 64 TTF Therapy 64 Targretin capsules 64 metastatic HRPC 64 Testosterone MDTS ® 64 chronic idiopathic thrombocytopenic purpura 64 #mg dose [002] 64 Xelox 64 relapsed MCL 64 RECIST criteria 64 Recurrent Glioblastoma 64 Dasatinib 64 ER CHOP 64 EndoTAG TM -1 64 Thorough QT 64 MERLIN TIMI 64 IV NSCLC 64 concurrent ITP 64 Maximum Tolerated Dose MTD 64 PRECiSE 64 omega interferon 64 Cimzia TM 64 ZACTIMA 64 blind placebo 64 multicentre randomized 64 pegylated interferon alfa 2b 64 adult chronic ITP 64 VIRAMUNE XR 64 randomized multicenter Phase III 64 registrational Phase 64 velafermin 64 CR nPR 64 hematopoietic cancers 64 virological response 64 Ophena TM 64 SCIg 64 COSIRA trial 64 underwent liver transplantation 64 Telintra 64 blinded placebo controlled 64 TACI Ig 64 heavily pretreated patients 64 rilonacept 64 biologic DMARD 64 Acute Ischemic Stroke 64 Insulin PH# 64 rtPA 64 clevidipine 64 CR# vcMMAE 64 intravenous cyclophosphamide 64 INCB# [001] 64 pomalidomide 64 fosbretabulin 64 Phase III psoriasis 64 MYCAMINE 64 lumiliximab 64 ACTIVE W 64 ADVANCE PD 64 LUMINATE 63 AIR CF2 63 intravenous bolus 63 #mg/m# [002] 63 elotuzumab 63 evaluable patients 63 Lipitor #mg 63 Dextofisopam 63 MoxDuo IR 63 metastatic CRC 63 evaluating tivozanib 63 Aptivus ® 63 partial remissions 63 baminercept 63 trials RCTs 63 epoetin alpha 63 EDEMA3 trial 63 BENICAR 63 Phase IIIb 63 EGFR TKI 63 INVEGA ® 63 LUX Lung 63 pharmacodynamic PD 63 rFVIIa 63 relapsed multiple myeloma 63 HIV HCV coinfected 63 dasatinib Sprycel ® 63 ATL# [001] 63 Velcade bortezomib 63 PREZISTA ritonavir 63 prospectively defined 63 achieved ACR# 63 Pharmacokinetics PK 63 mg/m2 administered 63 CINQUIL 63 azacitidine 63 maximal tolerated 63 titration phase 63 Phase IIa trials 63 Relapsed Multiple Myeloma 63 sunitinib malate 63 EOquin TM 63 mild renal insufficiency 63 plus prednisone prednisolone 63 multicenter multinational 63 Tipranavir 63 tipranavir r 63 insulin detemir 63 mcg albinterferon alfa 2b 63 dose proportionality 63 #mg/day [002] 63 dosage regimens 63 ixabepilone 63 Budesonide foam crofelemer 63 Decitabine 63 huN# DM1 63 aflibercept VEGF Trap 63 EURIDIS 63 paliperidone ER 63 MIRCERA 63 Hepatocellular Carcinoma HCC 63 MADIT II 63 HBeAg negative patients 63 anagrelide 63 argatroban 63 remission CR 63 cisplatin gemcitabine 63 prospective randomized placebo 63 relapsed AML 63 Prodarsan 63 oxymorphone ER 63 interferon ribavirin 63 evaluating Actimmune 63 BR.# 63 periodically reassessed 63 chemoradiation therapy 63 haematologic 63 SSRI SNRI 63 prospective randomized multicenter 63 #mg q8h 63 IIa trial 63 Phase #b/#a trial 63 intravesical infusion therapy 63 multicenter Phase III 63 Known hypersensitivity 63 RLAI 63 MEND CABG 63 AIR CF3 63 coinfected patients 63 ENGAGE AF TIMI 63 NEUVENGE 63 Phase IIIb study 63 alefacept 63 relapsed myeloma 63 lorcaserin Phase 63 BLA filing 63 HCD# [002] 63 Panzem R NCD 63 IV bolus 63 Hedgehog Pathway Inhibitor 63 JAK#/JAK# inhibitor CYT# 63 evaluating REVLIMID 63 Liraglutide Effect 63 Cloretazine R VNP#M 63 label dose titration 63 GALNS 63 catheter occlusion 63 telaprevir dosed 63 LEUKINE 63 paclitaxel poliglumex 63 BEXXAR Therapeutic Regimen 63 ALT flares 63 receiving immunosuppressive therapy 63 IFN alfa 63 randomized discontinuation 63 DAPT 63 assessing T DM1 63 Zevalin consolidation 63 guanfacine extended release 63 taxane refractory 63 ruboxistaurin 63 LEXIVA r 63 CLIRS trial 63 BCIRG 63 calculated creatinine clearance 63 Arikace 63 prospective multicentre 63 mCRC patients 63 im peramivir 63 CML CP 63 acute mania 63 Tanespimycin 63 saline placebo 63 Val HeFT 63 prospective nonrandomized 63 non splenectomized 63 Advaxis Phase 63 pharmacokinetic characteristics 63 mcg dose 63 ritonavir boosted lopinavir 63 plasma pharmacokinetics 63 Vimpat R 63 ASCEND HF 63 stage IIIb IV 63 Phase 1b clinical trials 63 placebo controlled multicenter 63 regorafenib 63 ponatinib 63 Enzastaurin 63 HIV uninfected 63 metastatic malignant 63 CRp 63 LymphoStat B belimumab 63 allogeneic SCT 63 BEXXAR 63 Phase III multicenter 63 renal denervation 63 PROSTVAC VF 63 VICTOR E1 63 pivotal bioequivalence 63 viral kinetic 63 doxorubicin cyclophosphamide 63 HGS ETR1 63 Sapacitabine 63 randomized controlled Phase 63 Phase Ia 63 apremilast 63 AVADO 63 PEARL SC 63 UVIDEM 63 Rate ORR 63 unresectable stage 63 EVIZON 63 corifollitropin alfa 63 cetrorelix pamoate 63 Teriflunomide 63 nonrandomized 63 Blinatumomab 63 pegylated interferon alfa 63 abiraterone acetate 63 dimebon latrepirdine 63 undergone splenectomy 63 receptor tyrosine kinase inhibitor 63 chronic GVHD 63 multicentre prospective 63 Heterozygous Familial Hypercholesterolemia 63 elacytarabine 63 HSCT 62 abacavir lamivudine 62 melphalan prednisone 62 reduce serum phosphate 62 neurologic progression 62 alicaforsen enema 62 Xanafide 62 PRIMO CABG2 62 postexposure prophylaxis 62 AeroLEF TM 62 initiate Phase 1b 62 confirmatory clinical 62 virologically suppressed 62 Refractory Angina 62 briakinumab 62 Xcellerated T Cells 62 APEX PD 62 Elotuzumab 62 Triapine R 62 unstable angina UA 62 FFNS 62 Tesmilifene 62 multicenter placebo controlled 62 Cloretazine ® 62 PRESEPT 62 Etanercept 62 AMEVIVE 62 oral picoplatin 62 AA Amyloidosis 62 avosentan 62 NeuroStar TMS Therapy 62 CK # administered 62 evaluating mipomersen 62 APTIVUS R 62 pharmacokinetic PK profile 62 controlled multicenter 62 TURBT 62 placebo controlled randomized 62 divalproex sodium 62 enzastaurin 62 Aryplase 62 smoldering multiple myeloma 62 subcutaneously administered 62 IMA# 62 #mg/m# [001] 62 dopamine partial agonist 62 MVA MUC1 IL2 62 E1 INT TM 62 evaluating Prochymal 62 biochemical relapse 62 unstable angina pectoris 62 atazanavir ritonavir 62 Randomised 62 mild hepatic impairment 62 PEGINTRON TM 62 mg administered orally 62 vicriviroc 62 vismodegib 62 Naive Patients 62 pegylated alpha interferon 62 opioid dependent 62 pertuzumab 62 Infusion reactions 62 BoNTA 62 HCV infected 62 asymptomatic metastatic 62 GLP1 agonist 62 MYTHOS trial 62 venlafaxine XR 62 EDARBI 62 eprodisate Fibrillex TM 62 statin monotherapy 62 virologic failure 62 tolerated dose MTD 62 ORENCIA ® 62 ChronVac C ® 62 BARACLUDE ® 62 oral deforolimus 62 adalimumab Humira 62 NeuroVax 62 prednisone prednisolone plus 62 mg ustekinumab 62 Phase IIa trial 62 Edge STudy 62 CAELYX 62 CCR5 receptor antagonist 62 mesalamine granules 62 Phase III VISTA 62 Octreolin 62 ARIKACE 62 TransVax 62 Index CDAI 62 NLX P# 62 ancrod 62 lintuzumab SGN 62 Hormone Refractory Prostate Cancer 62 Randomized Double blind 62 nucleotide analogue 62 AZOR 62 postintervention 62 daily subcutaneous injections 62 thrombin inhibiting aptamer 62 methotrexate therapy 62 severe hypercholesterolemia 62 metastatic renal cell 62 KRN# 62 5-fluorouracil/leucovorin 62 Initiated Phase 62 tocilizumab 62 CURE AF 62 GVAX 62 imatinib therapy 62 hour bronchodilation 62 Glypromate 62 Glufosfamide 62 Phase lll 62 ARIXTRA R 62 refractory colorectal cancer 62 Pivotal Phase III 62 phase IIb 62 low dose cytarabine 62 dexanabinol 62 UPLYSO 62 OvaRex MAb 62 CRLX# 62 previously untreated follicular 62 PLX STROKE targeting 62 romiplostim 62 Phase 1a 62 SPIRIT FIRST 62 OHR/AVR# 62 protease inhibitor PI 62 MCyR 62 dose escalation Phase 62 CCX# B 62 ToGA 62 #mg/day [001] 62 trastuzumab DM1 T DM1 62 phase 2a 62 PEG interferon 62 fibrinolytic therapy 62 relapsing MS 62 Taxotere ® 62 Betaferon ® 62 intra articular injection 62 herpetic keratitis 62 Doxil ® 62 μg dose 62 mg Pycnogenol 62 Tekamlo 62 Phase 2b kidney transplant 62 allogeneic stem cell 62 daily Infergen 62 ACAPODENE 62 Degarelix 62 TYKERB 62 Phase IIA 62 pramlintide metreleptin combination 62 Non inferiority 62 mg BID 62 infliximab monotherapy 62 IV metastatic melanoma 62 neoadjuvant treatment 62 CERVARIX 62 symptomatic hyponatremia 62 CCyR 62 Flu Cy 62 zileuton injection 62 MIST II 62 GRNVAC1 62 evaluating satraplatin plus 62 Engerix B 62 posaconazole 62 HBeAg + 62 null responder 62 uric acid lowering 62 corticosteroid dose 62 Phase Ib 62 recurrent metastatic 62 DLTs 62 symptomatic BPH 62 EBMT criteria 62 alemtuzumab treated 62 Meets Primary Endpoint 62 Folfox 62 mg eq 62 MVax R 62 trial evaluating Prochymal 62 Capesaris 62 mg kg BID 62 Plenaxis TM 62 motesanib 62 tipranavir ritonavir 62 K ras mutations 62 PROSTVAC ® 62 continuous intravenous infusion 62 amalgam fillings mercury vapor 62 Randomized Double Blind 62 ibandronate 62 Angiox ® 62 modified REGENESIS Phase IIb 62 ritonavir boosted danoprevir 62 anthracyclines taxanes 62 GnRH agonist 62 psoriatic arthritis PsA 62 phase IIIb 62 prucalopride 62 neoadjuvant 62 pegylated interferon peg IFN 62 TOLAMBA 62 Raptiva ® 62 multicenter randomized Phase 62 citalopram hydrobromide 62 custirsen 62 chlorambucil 62 Onrigin 62 efficacy endpoint 62 Cinquil 62 Pegylated Liposomal Doxorubicin 62 INFERGEN 62 Anturol TM 62 initiate multicenter 62 4mg/kg 62 number NCT# ClinicalTrials.gov 62 Hypotension 62 ABSSSI 62 Motesanib 62 advanced carcinoid 62 evaluating Xcytrin 62 alfa 2a 62 brivaracetam 62 eltrombopag 62 cytoreductive nephrectomy 62 TELCYTA 62 Vacc 4x 62 budesonide MMX Phase III 62 Phase III ADT 62 MP4OX 62 Romiplostim 62 Follicular Lymphoma 62 Cutaneous T 62 nucleoside naive 62 FOLFOX4 62 paricalcitol 62 VP# [004] 62 controlled multicenter Phase 62 ROCKET AF 62 q#h 62 darunavir ritonavir 62 dose escalation trial 62 TBC# 62 Multiple Ascending Dose 62 mapatumumab 62 REMINYL ® 62 bortezomib Velcade R 62 Hsp# Inhibitor 62 refractory systemic ALCL 62 orBec 61 achieved sustained virologic 61 imatinib resistant 61 IBS C 61 RSD# 61 HBeAg positive patients 61 Cardiotoxicity 61 HORIZONS AMI trial 61 maximal doses 61 mcg doses 61 ascending doses 61 SNT MC# 61 oxypurinol 61 Onrigin TM 61 pharmacokinetic pharmacodynamic 61 MoxDuo TM IR 61 Phase 1b trial 61 HBeAg seroconversion 61 Q#IR 61 mg RDEA# 61 mcg kg 61 AGHD 61 Sprycel dasatinib 61 metastatic castration resistant 61 BETAS 61 Pimavanserin 61 Testosterone MDTS R 61 CIMZIA R 61 Nesiritide 61 registrational trial 61 olanzapine LAI 61 bicifadine 61 peg interferon 61 stage IIIB 61 confirmatory Phase III 61 trastuzumab emtansine T DM1 61 octreotide LAR 61 CBLC# 61 intensive lipid lowering 61 Quinamed 61 Phase 2b Clinical Trial 61 surgical debulking 61 ISTODAX 61 Lofexidine 61 EDEMA3 61 HuMax CD4 61 HGS ETR2 61 DASISION 61 HCV NS5B polymerase 61 rimonabant #mg 61 Renal Impairment 61 metastatic hormone refractory 61 dose escalation 61 IFN α 61 Gleevec resistant 61 q8h 61 PROSTVAC TM 61 Newly Diagnosed Multiple Myeloma 61 TMC# C# 61 colorectal liver metastases 61 ORMD 61 ChronVac C R 61 metastatic malignant melanoma 61 tolerability pharmacokinetics 61 docetaxel chemotherapy 61 SUTENT ® 61 concomitant antibiotics 61 coadministration 61 ILLUMINATE 61 R#/MEM # 61 recurrent GBM 61 Eltrombopag 61 hepatitis C genotype 61 lesinurad 61 Phase 2b study 61 gadobutrol 61 multiple ascending dose 61 histologically confirmed 61 oxaliplatin Eloxatin 61 refractory gout 61 RhuDex ® 61 glufosfamide 61 favorable pharmacokinetic profile 61 Pharmacokinetic 61 AIM HIGH 61 rt PA 61 YERVOY 61 dietary questionnaires 61 ANCHOR trial 61 MKC# MT 61 CEQ# 61 EFAPROXYN 61 cisplatin chemotherapy 61 peginterferon 61 PANVAC VF 61 balsalazide tablet 61 palifermin 61 comparator arm 61 hypofractionated radiation 61 tipranavir 61 opioid induced bowel dysfunction 61 intravenous belinostat 61 papillary renal cell carcinoma 61 BAY #-# 61 ChronVac C 61 irbesartan 61 unfractionated heparin UFH 61 pharmacodynamics PD 61 adjuvant cisplatin 61 DOXIL 61 intravenous CK # 61 compound INCB# 61 dose limiting toxicities 61 platinum refractory 61 Phenoptin 61 Phase IIb trials 61 C1 INH deficiency 61 Tasimelteon 61 miglustat 61 COMFORT II 61 pharmacologically active isomer 61 TNF antagonist 61 Ceflatonin 61 cannabinor 61 tapentadol ER 61 axitinib 61 hA# 61 MIVI TRUST 61 TEMODAL 61 relapsed ovarian cancer 61 #mg BID [001] 61 demonstrated antitumor activity 61 TG MV 61 tarenflurbil 61 tesmilifene 61 Phe restricted diet 61 zileuton IV 61 vandetanib 61 anthracycline taxane 61 Pertuzumab 61 SUCCEED trial 61 clazosentan 61 Decompensated Heart Failure 61 rapid virologic response 61 Tasigna prolongs 61 peginterferon alfa 61 cytogenetic response 61 recurrent NSCLC 61 BrachySil TM 61 resminostat 61 urate lowering 61 immune thrombocytopenic purpura ITP 61 DCCR 61 valopicitabine 61 ABILIFY Injection 61 Kaplan Meier estimate 61 AVN# Phase 61 KYNAPID 61 bronchial thermoplasty 61 APEX AMI trial 61 ALISTA 61 remission induction 61 SAR# [004] 61 Diamyd ® 61 diabetic neuropathic pain 61 either acutely decompensated 61 phase IIb III 61 thalidomide Thalomid 61 HORIZONS AMI 61 HBeAg negative 61 temsirolimus 61 dirucotide MBP# 61 Amrubicin 61 HPTN 61 trabedersen 61 virologic responses 61 nalbuphine ER 61 refractory Hodgkin lymphoma 61 IMPACT DCM trial 61 Cladribine tablets 61 MoxDuo ® IR 61 EVEREST II 61 corticosteroid therapy 61 telaprevir dosing 61 lenalidomide dexamethasone 61 unique alkylating agent 61 myocardial revascularization 61 aldosterone antagonists 61 PASI scores 61 SPRYCEL ® 61 Plaque Psoriasis 61 CLIRS 61 mucosal healing 61 undetectable HCV RNA 61 rFSH 61 undetectable HBV DNA 61 folinic acid 61 GRNOPC1 contains 61 TNF antagonist therapy 61 Myelodysplastic Syndrome 61 EmbraceAC 61 Pegloticase 61 investigational protease inhibitor 61 maximally tolerated